 Ryan Lanning
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 1 | 2024 | 175 | 0.760 |
Why?
| | Immunotherapy | 1 | 2024 | 596 | 0.650 |
Why?
| | Melanoma | 2 | 2024 | 730 | 0.630 |
Why?
| | Skin Neoplasms | 2 | 2024 | 830 | 0.550 |
Why?
| | Trastuzumab | 1 | 2015 | 100 | 0.450 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 957 | 0.400 |
Why?
| | Receptor, ErbB-2 | 1 | 2015 | 325 | 0.390 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2024 | 208 | 0.350 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2045 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2017 | 628 | 0.280 |
Why?
| | Laryngeal Neoplasms | 2 | 2017 | 31 | 0.270 |
Why?
| | Microscopy | 2 | 2022 | 140 | 0.250 |
Why?
| | Breast Neoplasms | 3 | 2015 | 2104 | 0.240 |
Why?
| | Carcinoma | 2 | 2017 | 213 | 0.230 |
Why?
| | Hutchinson's Melanotic Freckle | 1 | 2024 | 3 | 0.230 |
Why?
| | Combined Modality Therapy | 2 | 2024 | 1201 | 0.210 |
Why?
| | Neoplasms | 6 | 2022 | 2454 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 544 | 0.180 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2019 | 65 | 0.170 |
Why?
| | Glottis | 2 | 2017 | 19 | 0.170 |
Why?
| | Drug Carriers | 1 | 2019 | 121 | 0.150 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 208 | 0.140 |
Why?
| | Oxygen | 4 | 2022 | 916 | 0.140 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 18 | 0.140 |
Why?
| | Meningioma | 1 | 2018 | 82 | 0.140 |
Why?
| | Cisplatin | 1 | 2019 | 299 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 377 | 0.140 |
Why?
| | Nose Neoplasms | 1 | 2017 | 20 | 0.140 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.140 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.140 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 94 | 0.140 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
| | Dexamethasone | 1 | 2019 | 352 | 0.130 |
Why?
| | Ear Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
| | Ear Canal | 1 | 2016 | 15 | 0.130 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2016 | 20 | 0.130 |
Why?
| | Misonidazole | 1 | 2016 | 1 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 34 | 0.130 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 48 | 0.120 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 124 | 0.120 |
Why?
| | Brachytherapy | 1 | 2016 | 104 | 0.120 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 129 | 0.120 |
Why?
| | Nanoparticles | 1 | 2019 | 376 | 0.120 |
Why?
| | Mastectomy | 1 | 2015 | 132 | 0.110 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 320 | 0.110 |
Why?
| | Quantum Dots | 1 | 2013 | 34 | 0.110 |
Why?
| | Protein Array Analysis | 1 | 2013 | 56 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2015 | 647 | 0.100 |
Why?
| | Humans | 18 | 2024 | 129847 | 0.100 |
Why?
| | Optics and Photonics | 2 | 2003 | 43 | 0.100 |
Why?
| | Aged | 8 | 2018 | 22107 | 0.090 |
Why?
| | Propensity Score | 3 | 2017 | 266 | 0.090 |
Why?
| | Spectroscopy, Near-Infrared | 2 | 2002 | 48 | 0.090 |
Why?
| | Neoplasm Metastasis | 3 | 2019 | 610 | 0.090 |
Why?
| | Middle Aged | 9 | 2018 | 31177 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1199 | 0.080 |
Why?
| | Fluorescence Recovery After Photobleaching | 1 | 2009 | 19 | 0.080 |
Why?
| | Cell Physiological Phenomena | 1 | 2009 | 18 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2017 | 7066 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2009 | 31 | 0.080 |
Why?
| | Palliative Care | 1 | 2015 | 706 | 0.080 |
Why?
| | Male | 9 | 2024 | 63759 | 0.080 |
Why?
| | Glucose | 1 | 2013 | 1003 | 0.070 |
Why?
| | Female | 15 | 2019 | 68829 | 0.070 |
Why?
| | Young Adult | 4 | 2017 | 12467 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 627 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 326 | 0.070 |
Why?
| | Blood Vessels | 1 | 2007 | 187 | 0.060 |
Why?
| | Adult | 7 | 2018 | 35634 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2016 | 251 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 530 | 0.060 |
Why?
| | Fetal Blood | 1 | 2007 | 318 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 851 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 382 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1501 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2002 | 58 | 0.050 |
Why?
| | Angiotensins | 1 | 2022 | 9 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2022 | 12 | 0.050 |
Why?
| | Losartan | 1 | 2022 | 14 | 0.050 |
Why?
| | Survival Rate | 2 | 2017 | 1872 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2007 | 749 | 0.050 |
Why?
| | Databases, Factual | 2 | 2017 | 1269 | 0.050 |
Why?
| | Mice | 5 | 2022 | 16983 | 0.050 |
Why?
| | Time Factors | 5 | 2017 | 6550 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2003 | 3397 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2009 | 253 | 0.040 |
Why?
| | Animals | 8 | 2022 | 35409 | 0.040 |
Why?
| | Mammography | 1 | 2002 | 146 | 0.040 |
Why?
| | Diffusion | 2 | 2011 | 117 | 0.040 |
Why?
| | Photons | 1 | 2000 | 67 | 0.040 |
Why?
| | Micelles | 1 | 2019 | 37 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 680 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5444 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 41 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 38 | 0.030 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 37 | 0.030 |
Why?
| | Organs at Risk | 1 | 2016 | 31 | 0.030 |
Why?
| | Tumor Hypoxia | 1 | 2016 | 6 | 0.030 |
Why?
| | Radiometry | 1 | 2016 | 48 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1248 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2003 | 893 | 0.030 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 69 | 0.030 |
Why?
| | United States | 3 | 2017 | 13913 | 0.030 |
Why?
| | Radiation Protection | 1 | 2016 | 38 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 168 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 220 | 0.030 |
Why?
| | Cochlea | 1 | 2016 | 100 | 0.030 |
Why?
| | Hypoxia | 1 | 2022 | 1087 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 282 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 379 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2017 | 471 | 0.030 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1282 | 0.030 |
Why?
| | Infant | 2 | 2017 | 9018 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 10241 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1214 | 0.020 |
Why?
| | Rats | 3 | 2009 | 5487 | 0.020 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 256 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 541 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2013 | 313 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 1989 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3185 | 0.020 |
Why?
| | Scattering, Radiation | 2 | 2002 | 100 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2628 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 337 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1560 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2018 | 14553 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 903 | 0.020 |
Why?
| | Lymphography | 1 | 2009 | 9 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2009 | 22 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 191 | 0.020 |
Why?
| | Chickens | 1 | 2009 | 188 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 298 | 0.020 |
Why?
| | Collagen Type I | 1 | 2009 | 118 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 82 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2009 | 143 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 3773 | 0.020 |
Why?
| | Image Enhancement | 1 | 2009 | 168 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 20451 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 514 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2007 | 82 | 0.020 |
Why?
| | Hyaluronic Acid | 1 | 2009 | 216 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2511 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 316 | 0.020 |
Why?
| | Glioblastoma | 1 | 2009 | 322 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2017 | 5772 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 7158 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4077 | 0.010 |
Why?
| | Indocyanine Green | 1 | 2002 | 19 | 0.010 |
Why?
| | Methylene Blue | 1 | 2002 | 23 | 0.010 |
Why?
| | Coloring Agents | 1 | 2002 | 78 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 10522 | 0.010 |
Why?
| | Fibroadenoma | 1 | 2002 | 2 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2780 | 0.010 |
Why?
| | Algorithms | 1 | 2009 | 1617 | 0.010 |
Why?
| | Premenopause | 1 | 2002 | 120 | 0.010 |
Why?
| | Breast | 1 | 2002 | 140 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 800 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2007 | 2378 | 0.010 |
Why?
| | Contrast Media | 1 | 2002 | 394 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 827 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1645 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2002 | 503 | 0.010 |
Why?
| | Water | 1 | 2002 | 442 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2002 | 549 | 0.010 |
Why?
| | Hemoglobins | 1 | 2000 | 339 | 0.010 |
Why?
| | Child | 1 | 2017 | 20962 | 0.010 |
Why?
|
|
Lanning's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|